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ABSTRACT 
Back ground: Drug related problems are common in hospitalized patients and may lead to increase hospital stay, health care cost and augment 
the risk of morbidity and mortality. 
Objective: The aim of the study is to examine the nature and frequency of drug related problems, to minimize drug related problems and to 
improve therapeutic outcome by pharmaceutical care provided by clinical pharmacist. 
Methodology: A prospective study was conducted in the cardiology department of a tertiary care hospital over a period of six months. Necessary 
demographic and clinical data was collected from the case records including drug history, other relevant details of the admitted patients and 
reviewed by the clinical pharmacist for drug related problems. 
Results: A total of 280 patient case sheets were reviewed during the study period, out of which 244 drug related problems were identified. The 
most common drug related problem was found to be drug interactions (58.6%) followed by untreated indication (19.26%) and drug use without 
indication (15.57%). The most frequent suggestions provided by the intervening pharmacist were drug discontinuation (5.32%), addition of a 
new drug (5.32%) and change of dosage form (4.5%). 
Conclusion: Drug related problems are common among medical ward patients. Routine participation of clinical pharmacist in clinical medical 
rounds facilitates the identification of drug related problems and the current study highlights the importance of pharmacist in a multidisciplinary 
team of reviewing drug therapy for identification and resolution of DRPs which helps in achieving better therapeutic outcomes and improved 
patient care. 
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INTRODUCTION 
Cardiovascular disease is a major public health problem and 
one of the leading causes of premature death throughout the 
world, and contributes substantially to increased health care 
costs. The most common underlying pathology expected to 
cause cardiovascular diseases is atherosclerosis. It is 
potentially a serious condition and one of the most common 
causes of cardiovascular diseases develops over many years 
and they are often fatal before any medical care can be given. 
The early identification and modification of risk factors has 
been shown to reduce mortality and morbidity in people 
with diagnosed or undiagnosed cardiovascular disease1. 
People with established cardiovascular disease have to give 
special care as they are at very high risk of recurrent events. 
Cardiovascular disease is usually seen in middle-aged or 
elderly men and women and it is expected that 
atherosclerosis is the main under pathology leading to 
coronary artery disease, cerebral artery disease and 
peripheral artery disease. Though several forms of therapy 
exist to prevent the coronary, cerebral and peripheral 
vascular events, decisions about whether to initiate specific 
preventive action, and with the degree of intensity, should be 
guided by estimation of the risk of any such vascular event. 
Management of major cardiovascular risk factors can be 
done through changes in the sedentary lifestyle and 
prophylactic drug therapies2. 
The presence of cardiovascular risk factors such as tobacco 
use, an unhealthy diet and physical inactivity (which 
together result in obesity), elevated blood pressure 
(hypertension), abnormal blood lipids (dyslipidemia) and 
elevated blood glucose (diabetes) and continuous exposure 
to them influences the progression of atherosclerosis. This 
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may result in unstable atherosclerotic plaques, narrowing of 
blood vessels and obstruction of blood flow to vital organs, 
such as the heart and the brain3. The clinical manifestations 
of these diseases include angina, myocardial infarction, 
transient cerebral ischemic attacks and stroke. Drug related 
problems may arise at all stages of the medication process 
from prescription to follow-up of treatment. Most of the 
problem usually occurs on administration, dispensing and 
during the patient’s use of a medicinal product, but lack of 
proper follow-up and reassessment of medical treatment by 
the physician is also a major problem. A Drug related 
problem (DRP) is defined as, an any event or circumstance 
involving drug treatment that interferes or potentially 
interferes with the patient achieving an optimum outcome of 
medical care4. 
Increased number of medications, complexity of drug 
regimens and availability of new drug therapies potentially 
increase the risks of patient for iatrogenic adverse drug 
events in hospitals. This can lead to prolonged hospital stay 
and increased health care costs. So the injury or death that 
may occur as a result of drug related problems has to be 
evaluated so as to reduce the occurrence of similar events in 
future. Drug-related problems occur more frequently in 
hospitalized patients where multiple changes are being 
made in patient’s medication regimens and lack of continuity 
of care may be accompanied. The most common problems 
associated with drug use are many and includes 
inappropriate medication prescribing, discrepancies 
between prescribed and actual regimens, poor adherence, 
drug interactions, inappropriate use, patients monitoring 
and inadequate surveillance for adverse effects etc. Drug 
related problems lead to substantial morbidity, mortality as 
well as increased health care expenditure which in turn 
affect the patient’s quality of life. A medication-related 
problem is an event or circumstance involving medication 
therapy that actually or potentially interferes with an 
optimum outcome for a specific patient5,6. 
The main objective of medication use in any disease is to 
optimize drug therapy with minimum safety related 
problems within the frame work of pharmaceutical care 
plan. The goal of pharmaceutical care is to optimize the drug 
therapy, achieve positive clinical outcomes within realistic 
economic expenditures and improve patient's health related 
quality of life. Availability of new drug therapies and 
increased use of medications may potentially increase the 
risks for patients to iatrogenic adverse drug events in the 
hospitals. Iatrogenic adverse events are important for 
consideration because they not only prolong the hospital 
stay but also increase the health care. 
Aim 
To minimize drug related problems and to improve 
therapeutic outcomes by pharmaceutical care provided by 
clinical pharmacist. 
Objectives 
 To examine number and nature of drug related problems 
in patients with cardiovascular diseases and to 
demonstrate the role of pharmacist in ensuring safe and 
efficient use of medications in daily practice in the 
inpatient settings. 
 To provide pharmaceutical care interventions based on 
the existing DRPS. 
MATERIALS AND METHODS 
Study site: 
Tertiary care Hospital, Bengaluru, Karnataka, India. 
Study design: 
This is a prospective and observational study. 
Study period: 
The study will be carried out for a period of six months. 
Study criteria: 
Inclusive criteria 
 Patients admitted with cardiovascular diseases 
 Patients of both sex and above 18yr old undergoing 
treatment on the cardiology inpatient wards of the 
hospital are included in the study. 
Exclusive criteria 
 Patients undergoing treatment less than one day of 
hospital stay are excluded from the study. 
 Patient undergoing treatment on outpatient basis 
Source of data: 
The data were collected from treatment chart, laboratory 
report and patient medical records. 
Study procedure: 
It was a prospective observational study carried out for a 
period of 6 months in hospitalized cardiovascular patients 
admitted in the cardiology department. All the patients with 
cardiovascular diseases admitted in the cardiology 
department of both sex have been included in the study. All 
the cases were reviewed by the clinical pharmacists and 
those who met the study criteria were followed and drug 
therapy details were recorded in the suitable designed data 
collection form as per the need of the study. The 
classification includes drug use without indication, untreated 
indication, improper drug selection, over dose, sub 
therapeutic dose, adverse drug reactions, and drug 
interactions. The acceptance level for each intervention was 
also recorded as either accepted or nor accepted. Similarly, 
whether or not any change in drug therapy was also noted. 
Data collection form: 
The data collection form was developed by referring 
available literatures and objective requirements. It includes 
patient demographics, final diagnosis chart, past medical 
history, treatment chart, laboratory results. 
Documentation:  
The data collected from the patients was documented, for 
further analysis. Microsoft excel software is used for 
statically analysis. 
RESULTS 
A prospective observational study was conducted over a 
period of 6 months in cardiology department at BGS global 
hospital, Bengaluru, Karnataka, India. During the study 280 
patients were enrolled. 
Table 1: Gender distribution 
Gender No. of patients Percentage (%) 
Male 214 76.4% 
Female 66 23.5% 
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Figure 1: Chart representing gender distribution 
The total number of subjects enrolled in this study was280, 
out of which 214 (76.4%) were found to be male and 66 
(23.5%) were found to be female, as represented in above 
diagram. 
 
Table 2: Distribution of patients according to age group 
Age group (years) No of patient(n=91) Percentage (%) 
21-30 8 2.85% 
31-40 20 7.14% 
41-50 60 21.42% 
51-60 78 27.85% 
61-70 88 31.42% 
71-80 22 7.85% 
>81 4 1.42% 
 
 
Figure 2:  Distribution according to age (in years) group 
Out of the 280 subjects, 8 (2.5%) were under the age group 
of 21-30 years, 20(7.14%) were under the age group of 31-
40, 60 (21.42%) were under the age group of 41-50, 78 
(27.85%) were under the age group of 51-60, 88 (31.42%) 
under the age group of 61-70, 22 (7.85%)under the age 
group of 71-80, 4 (1.42%) under the age group of >81 as 
represented in above diagram. 
Table 3: Distribution of patients based on 
length of the stay 
Length of stay No. of patients (n=280) Percentage (%) 
1-3days 152 54.2 
4-6days 105 37.5 
7-9days 21 7.5 
>10days 2 0.71 
 
 
Figure 3: Distribution of patients based on 
length of the stay 
Out of the total number of subjects, 152 patients were stayed 
for 1-3days, 105 patients were stayed for 4-6days, 21 
patients for 7-9 days and 2 patients for more than 10 days as 
represented above. 
Table 4: Distribution of the patients according to the no. 
of medications 
No. of medications No. of patients Percentage (%) 
1-5 29 10.35% 
6-10 112         40.0% 
>10 139         49.64% 
 
 
Figure 4: Distribution of patients according to no. of 
medications  
Out of 280 patients, 29 patients received <5medication, 112 
patients received 6-10 medications, 139 patients received 
>10 medications. 
Table 5: Comorbidities of patients in cardiology 
department 
Comorbidity Number Percentage 
0 Comorbidity 26 9.20% 
1 Comorbidity 135 48.20% 
2 Comorbidities 84 30% 
3 Comorbidities 28 10% 
4 Comorbidities 6 2.10% 
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Figure 5: Comorbidities of patients in cardiology department 
 
Out of the total number of subjects, 9.20% patients have 0 comorbidity, 48.20% patients have 1 comorbidity, 30% patients have 
2 comorbidities, 10% patients have 3 comorbidities and 2.10% patients have 4 comorbidities. 
 
Table 6: Patients with one comorbid condition 
One-comorbid condition Number Percentage 
Hypertension 38 13.57% 
Diabetes Mellitus 32 11.40% 
Anemia 2 0.71% 
Deep vein thrombosis 2 0.71% 
Bronchial Asthma 2 0.71% 
 
 
Figure 6: Patients with one comorbid condition 
 
Out of the total number of subjects, 13.57% patients have hypertension, 11.40% patients with diabetes mellitus, 0.71% patients 
with anemia, 0.71% patients with deep vein thrombosis and 0.71% patients with bronchial asthma. 
 
Table 7: patients with two comorbid conditions 
Two comorbidity condition Number Percentage 
DM+HTN 33 11.78% 
HTN+RHD 2 0.71% 
HTN+DVT 2 0.71% 
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Figure 7: Patients with two comorbid conditions  
Out of the total number of subjects, 11.78% patients were 
diagnosed with diabetes mellitus + hypertension, 0.71% 
patients were diagnosed with hypertension + rheumatic 
heart disease and 0.71% patients were diagnosed with 
hypertension + deep vein thrombosis. 
 
Table 8: Patients with three comorbid conditions 
Three comorbid condition Number Percentage 
DM + HTN + Hypothyroidism 3 1.07% 
DM + HTN + Anemia 2 0.71% 
 
 
 
Figure 8: Patients with three comorbid conditions  
Out of the total number of subjects, 1.07% patients were 
diagnosed with diabetes mellitus + hypertension + 
hypothyroidism, 0.71% patients were diagnosed with 
diabetes mellitus + hypertension + anemia. 
Table 9: Drug use without indication 
Drug Number Percentage 
Emeset 16 25.30% 
Alprazolam 11 17.40% 
Duphalac 8 12.60% 
Duolin 3 4.70% 
 
 
Figure 9: Drug use without indication 
Few drugs often used without indication include emeset 
25.30%, alprazolam 17.40%, duphalac 12.60% and duolin 
4.70%. 
  Table 10: Untreated indication 
Condition Number Percentage 
Dyspnea 26 49.0% 
Anemia 13 13.20% 
Cough 5 9.40% 
Constipation 3 5.60% 
 
 
Figure 10: Untreated indication  
Out of the total number of subjects, the some of the 
untreated indications are dyspnea (49%), anemia (13.2%), 
cough (9.40%) and constipation (5.60%). 
 
Table 11: Adverse drug reactions 
Class Drug ADR 
No. of 
patients 
Suggestion 
given and 
taken 
Suggestion 
given not 
taken 
Neither 
given nor 
taken 
Anti-diabetic Insulin Hypoglycemia 4 - - 4 
Diuretic Furosemide Hypokalemia 5 3 2 - 
Statins Atorvastatin Insomnia 4 - - 4 
Beta blocker Carvedilol Cough 3 3 - - 
2 2 
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Figure 11: Drug interactions 
Out of the total number of subjects, we found 28.90% major drug interactions (81), 22.10% moderate drug interactions (62) and 
1.78% minor drug interactions (5) and these are theoretically observed interventions. 
Table 12: Frequently occurring major DIs 
Major interactions Effect Frequency 
Clopidogrel+aspirin Increased risk of bleeding 195 
Heparin+aspirin Increased risk of bleeding 183 
Clopidogrel+aspirin Increased risk of bleeding 145 
Aspirin+furosemide Reduced furosemide effect 71 
Aspirin+spironolactone Reduced diuretic effect 39 
Aspirin+metformin Increased risk of hypoglycemia 27 
Aspirin+tirofiban Increased risk of bleeding 26 
Aspirin+ticagrelor Increased risk of bleeding 25 
Aspirin+insulin Increased risk of hypoglycemia 25 
Amlodipine+clopidogrel Decreased anti-platelet effect 24 
Digoxin+aspirin Increased risk of bleeding 23 
 
Out of 280 patients, 195 patients were developed increased risk of bleeding with clopidogrel+aspirin and 23 patients were 
developed with increased risk of bleeding with digoxin+aspirin. 
Table 13: Frequently occurring moderate interactions 
Moderate interactions Effect Frequency 
Clopidogrel+atorvastatin Decreased effect  of clopidogrel 192 
Aspirin+metformin Increased BP 69 
Ranolazine+atorvastatin Increased risk of myopathy 61 
Carvedilol+aspirin Increased risk of BP 38 
Heparin+ticagrelor Increased risk of bleeding 26 
Telmisartan+spironolactone Increased risk of hyperkalemia 19 
  
Out of 280 patients 192 patients showed decreased effect of clopidogrel with clopidogrel+atorvastatin and 19 patients were 
developed increased with telmisartan+spironolactone. 
Table 14: Types of drug related problems 
Types of DRPs Number Percentage (%) 
Drug use without indication 38 15.57 
Sub therapeutic dose 0 0 
Untreated indication 47 19.26 
Failure to receive drug 0 0 
Adverse drug reaction 16 6.55 
Overdose 0 0 
DI 143 58.6 
Improper drug selection 0 0 
 
Among 280 patients followed during the study period, a total of 244 DRPs (99.98%) were identified. Out of 58.6% were found to 
be drug interactions (143), 19.26% were found to be untreated indication (47), 15.57% were found to be drug use without 
indication (38) and 6.55% were found to be adverse drug reaction (16). 
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Table 15: Types of pharmacist interventions to prevent 
DRPs 
Drug choice Number Total 
Drug discontinuation 13 5.32% 
Addition of a new drug 13 5.32% 
Change of dosage form 11 4.5% 
Decrease the dose 10 4.09% 
 
Types of pharmacist interventions given to prevent DRPs 
were found to be 5.32% drug discontinuation (13), 5.32% 
addition of a new drug (13), 4.5% change of dosage form 
(11) and 4.09% decrease the dose (10). 
Table 16: Results of pharmacist interventions 
Recommendations Result 
Suggestion given and taken 42 
Suggestion given not taken 23 
Neither given nor taken 215 
 
Outcomes of the recommendation concerning drug related 
problems are suggestion given and taken 42, suggestion 
given not taken 23 and neither given nor taken 215. 
DISCUSSION 
Among 280 patients followed during the study period, a total 
of 244 DRPs were identified. In the total population 214 
were male patients and 66 were female patients. Male 
population was more due to increased medication use 
because of their multiple comorbid conditions and also 
possibility of various risk factors like smoking, alcoholism 
and sedentary life style compared to female population. The 
age group was categorized in to four groups such as 21-40, 
41-60, 61-80, and more than 80. The incidence was DRPs 
was high (49.3%) in patients aged between 41-60 years. 
Among the number of drugs, patients receiving more than 6 
drugs have more drug related problems. In the study 40% of 
the patients received 6-10drugs, 49% of the patients 
received >10 drugs and 10.3% patients received <5drugs. 
These findings were similar to the study carried out by celin 
et al.7, which showed that 50% of overall population took 
more than 10 medications and developed DRP’s. Patients 
were categorized according to the number of comorbid 
conditions in which 135 patients have single comorbidity, 84 
have two comorbidities and 28 has three comorbidities. This 
observation was similar to the study conducted by Seuma J 
et al.7, of which 48.20% of the population has at least one 
comorbid condition. 
This indicates that special attention should be done in such 
group of patients where regular review of drug therapy 
might help potentially to decrease the drug related problem. 
Drug interactions were the most common drug related 
problem observed in the study (58.6%) followed by 
untreated indication (19.26%) and drug use of all the drug 
interactions 28.90% were major drug interactions (81), 
without indication (15.57%), Adverse drug reactions 
(6.55%), overdose (4.09%). 22.10% were moderate 
interactions (62) and 1.78% were minor interactions (5). 
This observation was in contrast with the study conducted 
by Celin et al.7, in which potential drug interaction was found 
to be high. In the present study the therapeutic agents most 
commonly involved in drug interactions were anti-platelet 
agents, anti-hypertensives and GI drugs.  
In our study the untreated indication was found to be 
19.26% and some of the untreated indications are dyspnea 
(49%), anemia (13.2%), cough (9.4%), and constipation 
(5.6%). This was found to be similar to the observational 
study conducted by Celin et al.7, where 7% of the untreated 
indication account for the total drug related problems. In this 
study, drug use without indication accounts for 15.57%. Few 
drugs often used without indication include ondansetron 
(25.30%), alprazolam (17.40%), duphalac (12.60%), duolin 
(4.70%). In some cases, anti-emetics have been prescribed 
for vomiting but it has been continued even after the 
vomiting has stopped. 
These study findings are in contrast with the study carried 
out by Alagiriswami et al.8, which shows that drug use 
without indication accounts for 18% of total DRP’s 
respectively. Adverse drug reactions can cause a significant 
financial burden to the health care system. In the study we 
observed 6.55% of the adverse drug reactions are 
hypoglycemia due to insulin in diabetic patients, 
hypokalemia due to furosemide, insomnia due to 
atorvastatin, and cough due to carvedilol. 
Types of pharmacist’s intervention were drug 
discontinuation and addition of new drug (5.32%), change of 
dosage form (4.5%) and decrease in the dosage form 
(4.09%). These findings were similar to the study carried out 
by Rani Reema Abraham2 and Alagiriswami et al.8, where 
drug discontinuation, addition of a new drug, change of 
dosage form were the interventions provided by the clinical 
pharmacists. The acceptance of pharmacist’s interventions 
was found to be high i.e. 42 cases. 23 recommendations were 
accepted but the therapy was not changed perhaps due to 
lack of proper information which needs to strengthen the 
suggestions provided or the suggestions provided were 
thought to be insignificant. In 215 cases the suggestions 
were neither suggested nor the drug therapy changed. 
This was similar to the study carried out by Reema 
Abraham2, where outcomes of the pharmacist interventions 
were divided as suggestion accepted and taken, suggestion 
accepted but therapy not changed and neither suggestion 
nor therapy changed. This indicates that a clinical 
pharmacist can contribute to better patient care if involved 
in the health care team. The overall findings from our study 
was that pharmacists could identify some drug related 
problems, prompt and proper interventions will help in 
achieving better patient care that can lead to improve the 
quality of care and drug therapy. 
CONCLUSION 
The present study demonstrated that patients with 
cardiovascular diseases suffer from large number of drug 
related problems that may be solved or prevented by 
pharmacist interventions. Out 0f 280 patients a total of 244 
drug related problems were identified. The most frequently 
identified drug related problems were drug interactions 
(58.6%) followed by untreated indications (19.26%) and 
drug use without indications (15.57%). Policy makers should 
consider implementing systematic medication reviews on 
regular basis to achieve and maintain high quality drug 
treatment in general hospitals. 
Types of pharmacist interventions were drug 
discontinuation, addition of new drugs, change of dosage 
form and decrease in the dosage form. The acceptance of 
pharmacist’s interventions was found to be in 42 cases. So 
review of the patient’s drug therapy by clinical pharmacist 
can positively influence the patient’s outcomes and quality of 
care. In the present study drug related problems were 
identified, reported and relevant interventions were made 
accordingly thereby improved therapeutic outcome and 
patient quality of life. 
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The present study highlights the fact that clinical pharmacist 
can play a very important role in the health care 
management by rationalizing and optimizing the drug 
therapy in achieving better quality of life. This study strongly 
suggested that, there are more drug related problems in 
cardiovascular patients. Hence this study clearly showed that 
the pharmaceutical care is very much essential in 
cardiovascular patients. 
ACKNOWLEDGEMENT 
The authors wish to thank the management of PES College of 
Pharmacy, Bengaluru, Karnataka, India for providing 
necessary equipment for research, constant encouragement, 
facilities and support. 
CONFLICTS OF INTEREST 
The author declares that there is no conflict of interest to 
disclose. 
REFERENCES 
1. Shareef J, Sandeep B, Shastry CS. Assessment of drug related 
problems in patients with cardiovascular diseases in a tertiary 
care teaching hospital. Journal of pharmaceutical care 2014; 
2(2):70-6. 
2. Rani Reema Abraham. Drug related problems and reactive 
pharmacists interventions for inpatients receiving cardio 
vascular drugs. International journal of basic medical sciences 
and pharmacy 2013; 3(2):2049-4963. 
3. Viktil KK, Blix HS. The impact of clinical pharmacists on drug 
related problems and clinical outcomes. Clin Pharmacol Toxicol 
2008; 102(3):275-80. 
4. Ragesh G, Sindhubharathi A, Usharani M, Srinivasulu A. 
Assessment of clinical pharmacy services to cardiology 
department in tertiary care teaching hospital. International 
journal of pharmacy and pharmaceutical sciences 2014; 
6(2):0975-1491. 
5. Gashaw Binega Meknonnen, Mequanent Kassa Biarra, Masho 
Tigabe Tekle, Akshaya Srikanth Bhagavathula. Assessment of 
Drug Related Problems and its Associated Factors among 
Medical Ward Patients in University of Gondar Teaching 
Hospital, Northwest Ethiopia: A Prospective Cross-Sectional 
Study. Journal of Basic and Clinical Pharmacy 2017; 8: 016-21. 
6. Zieske AW, Malcom GT, Strong JP. Natural history and risk 
factors of atherosclerosis in children and youth: The PDAY 
study. Pediatr Pathol Mol Med 2002; 21(2):213-37. 
7. Celin AT, Seuma J, Ramesh A. Assessment of drug related 
problems in stroke patients admitted to a south Indian tertiary 
care teaching hospital. Indian J Pharm Pract 2012; 5(4):28–33. 
8. Alagiriswami B, Ramesh M, Parthasarathi G, Basavanagow 
dappa H. Clinical pharmacist initiated changes in drug therapy 
in a teaching hospital. Indian J Pharm Pract 2009; 1(2):36-45. 
 
 
  
 
